IP Library Granted Patent US 8,575,190
Granted Patent B2
US 8,575,190 · App. 12/742,351 · Granted Nov 5, 2013

Method of preventing or ameliorating psoriasis using pyrroloquinoline quinone compounds

Inventors: Ayako Kamimura (Ibaraki, JP); Toshikazu Kamiya (Ibaraki, JP); Masahiko Nakano (Niigata, JP); Kazutoshi Kikkawa (Chiba, JP)
Assignee: Mitsubishi Gas Chemical Company, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,575,190
App. No.
12/742,351
Granted
Nov 5, 2013
Kind
B2
Abstract

The present invention provides a method for preventing or ameliorating skin psoriasis by applying as an active ingredient, a compound represented by general formula (I) or a salt thereof: (wherein R 1 , R 2 , and R 3 simultaneously or separately represent a lower alkyl, lower alkenyl, lower alkynyl, aralkyl, araryl, or phenyl group, or a hydrogen atom).

Claims (11)

1. A method for ameliorating dermatological symptoms of psoriasis, comprising administering 0.5 to 10,000 mg of a compound represented by formula (I) or a salt thereof to a patient in need thereof:

wherein R 1 , R 2 , and R 3 independently represent a lower alkyl, lower alkenyl, lower alkynyl, aralkyl, araryl, or phenyl group, or a hydrogen atom, with the proviso at least one of R 1 , R 2 , and R 3 represents a hydrogen atom, and

the compound of formula (I) or the salt thereof is the only active compound administered to said patient.

2. A method for ameliorating dermatological symptoms of psoriasis, comprising administering 0.5 to 10,000 mg of a compound represented by formula (I) or a salt thereof to a patient in need thereof:

wherein R 1 , R 2 , and R 3 independently represent a lower alkyl, lower alkenyl, lower alkynyl, aralkyl, araryl or phenyl group, and

the compound of formula (I) or the salt thereof is the only active compound administered to said patient.

3. A method for ameliorating dermatological symptoms of psoriasis, comprising administering 0.5 to 10,000 mg of a compound represented by formula (I) to a patient in need thereof:

wherein R 1 , R 2 , and R 3 each represent a hydrogen atom, and

the compound of formula (I) is the only active compound administered to said patient.

4. The method according to any one of claim 1 , 2 or 3 wherein 0.5 to 5,000 mg of the compound represented by formula (I) or a salt thereof is administered to said patient.

5. The method according to claim 4 , wherein 0.5 to 1,000 mg of the compound represented by formula (I) or a salt thereof is administered to said patient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2012
From: KYOWA HAKKO BIO CO., LTD.; MITSUBISHI GAS CHEMICAL COMPANY, INC.
To: MITSUBISHI GAS CHEMICAL COMPANY, INC.
Reel/Frame 028286/0139 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2010
From: KAMIMURA, AYAKO; KAMIYA, TOSHIKAZU; NAKANO, MASAHIKO; KIKKAWA, KAZUTOSHI
To: KYOWA HAKKO BIO CO., LTD.; MITSUBISHI GAS CHEMICAL COMPANY, INC.
Reel/Frame 024367/0236 →
Priority Claims (1)
JP 2007-296022 · Nov 14, 2007 · national
Continuity (1)
Related Publication 20100261749A1 · Oct 14, 2010